# US 2019/0072550 A1 · Predictive Markers Useful in the Treatment of Wet Age-Related Macular Degeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0072550 A1
- Document ID: US20190072550A1
- Status: Published application
- Kind: A1
- Application number: 16/080,628
- Filed: 2017-02-28
- Published: 2019-03-07
- Earliest claimed: 2016-02-29
- Assignees: maintect GmbH
- Applicants: maiunfect GmbH
- Inventors: Franz Grus; Christina Korb; Norbert Pfeiffer
- Web page: https://patentgrep.com/patent/US20190072550A1

## CPC

- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6854: {Immunoglobulins}
- G01N 2800/164: Retinal disorders, e.g. retinopathy
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention is directed to the use of biomarkers to determine responsiveness of an individual with wet AMD to treatment with a VEGF antagonist, to diagnose and distinguish dry and wet AMD and to determine the risk of conversion of a dry AMD disease to a wet AMD disease.

## Claims

### Claim 1

A method of determining the responsiveness of an individual with wet AMD to treatment with a VEGF antagonist, the method comprising:
(i) isolating a sample from an individual having wet AMD;
(ii) determining the quantity of one or several autoantibodies selected from Group A antibodies directed against MAPK3 , OGFR, PolyRp2, Chromosome 17, EIFA1, GPX4, SRP14, Gamma-synuclein, Jo-1, Pre-Albumin, GPD2, AP1M1, EN01-H7, PRG2, ATP synthase, GNB1-A3, TUBB3, HSP 60, ICA1, SELO, SOD, EN02 and
(iii) assigning the individual as a VEGF antagonist responder if the sample has an increased or decreased amount of selected antibodies as in (ii), compared to a control.

### Claim 2 (depends on 1)

The method according to claim 1 comprising:
(i) isolating a sample from an individual having wet AMD;
(ii) determining the quantity of antibodies selected from a subgroup A-1 of the Group A antibodies directed against MAPK3, OGFR, SRP14, EN02, SOD, Pre-Albumin, Jo-1, PolyRp2, Chromosome 17, EIFA1; and
(iii) assigning the individual as a VEGF antagonist responder if the sample has an increased or decreased level of selected antibodies as in (ii) compared to a control.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the level of antibodies in the sample is increased by at least 10%, by 20%, by 30%, by 40%, by 50%, by 100%, by 150%, by 200%, by 250%, preferably by 25%-150%, more preferably by 50-100%, compared to a control value derived from healthy individuals.

### Claim 4

(canceled)

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method according to claim 1, wherein the determination of the quantity of antibodies is done using Western blot or immunoblot assays, enzyme-linked immunoabsorbent assays (ELISA), radioimmunoassays, realtime PCR, microarrays, lateral flow, microfluidic, bead based assays, mass spectrometry.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the sample is a fluid sample such as blood, serum, tears, saliva, urine, a cell sample such as buccal cells, aqueous humor or vitreous body of the eye.

### Claim 8

A method of determining whether an individual suffers from dry AMD and/or wet AMD, the method comprising:
isolating a sample from a subject;
determining the quantity of one or several antibodies selected from Group B antibodies directed against alpha-synuclein, SELO, SPRY, GAPDH-H2, Annexin-V, THAP, VTI-B, HSP10, ESD, PKC80, AC02-C2, OGFR, PBP-I2, CAZ-C3, EIFA1, MAPK3, EN01-H7, Chromosome17, Aconitate Hydratase, GPX4; and
determining that the individual suffers from the dry and/or the wet AMD disease if the amount of the selected Group B autoantibodies is increased or decreased, in particular increased or decreased by at least 20%, at least 30%, at least 40%, at least 50% or at least 75% compared to a control.

### Claim 9 (depends on 8)

The method according to claim 8 comprising
isolating a sample from a subject;
determining the quantity of one or several antibodies of a subgroup B-1 of the Group B antibodies directed against alpha-synuclein, SELO, SPRY, GAPDH-H2, Annexin-V, THAP, VTI-B, HSP10;
determining that the individual suffers from the dry and/or the wet AMD disease if the amount of the selected Group B autoantibodies is increased or decreased, in particular increased or decreased by at least 20%, at least 30%, at least 40%, at least 50% or at least 75%, compared to a control.

### Claim 10

A method to determine that an individual with dry AMD is at risk to develop wet AMD, the method comprising:
isolating a sample from a subject;
determining the quantity of one or several antibodies selected from autoantibodies which are members of Group A and/or of Group B wherein Group A antibodies are directed against MAPK3, OGFR, PolyRp2, Chromosome 17, EIFA1, GPX4, SRP14, Gamma-synuclein, Jo-1, Prealbumin, GPD2, AP1M1, EN01-H7, PRG2, ATP synthase, GNB1-A3, TUBB3, HSP 60, ICA1, SELO, SOD, EN02 and wherein Group B antibodies are directed against alpha-synuclein, SELO, SPRY, GAPDH-H2, Annexin-V, THAP, VTI-B, HSP10, ESD, PKC80, AC02-C2, OGFR, PBP-I2, CAZ-C3, EIFA1, MAPK3, ENO1-H7, Chromosome17, Aconitate Hydratase, GPX4
determining that the individual is at risk to develop wet AMD if the amount of the selected antibodies is decreased or increased, in particular decreased or increased by at least 20%, at least 30%, at least 40%, at least 50%, or at least 75% compared to control values.

### Claim 11 (depends on 10)

The method according to claim 10 comprising:
isolating a sample from a subject;
determining the quantity of one or several antibodies selected from autoantibodies which are members of preferred subgroups A-1 and/or B-1 of Groups A and B, wherein antibodies of the subgroup A-1 are directed against MAPK3, OGFR, SRP14, EN02, SOD, Pre-Albumin, Jo-1, PolyRp2, Chromosome 17, EIFA1; and
wherein antibodies of subgroup B-1 are directed against alpha-synuclein, SELO, SPRY, GAPDH-H2, Annexin-V, THAP, VTI-B, HSP10;
determining that the individual is at risk to develop wet AMD if the amount of the selected antibodies is decreased or increased, in particular decreased or increased by at least 20%, at least 30%, at least 40%, at least 50%, or at least 75% compared to control values, in particular control values derived from subjects who are healthy and/or derived from subjects with dry AMD and/or with wet AMD.

### Claim 12 (depends on 10)

The method according to claim 10, comprising:
isolating a first sample from a subject;
isolating a second sample from the subject within a time period of about 2 weeks, of about 1 month, of about 2 months, of about 6 months, of about 12 months, of at least about 12 months after the first sample;
determining the quantity of one or several selected antibodies from Group A and/or from Group B or from subgroup A-1 or B-1 in each sample;
determining that the individual is at risk to develop wet AMD if the quantity of antibodies directed against OGFR is at least 20% decreased or increased in the second sample compared to the first sample.

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)
